As part of our coverage of ADA 2021, the Endocrinology Network has compiled a curated list of the most viewed and impactful dates from this year’s conference. Our list includes 5 topics of coverage, including how the cost of diabetes management weighs on progress, the SURPASS program, a trio of FIDELIO-DKD analyzes, exciting news about semaglutide, and a review of the data from the SCORED and SOLOIST studies .
Editor’s note: Clicking on the slides will take you back to the reference article. If there are multiple articles on a slide, links to those articles can be found under the slideshow.
Below you will find links to the individual contents examining pre-determined analyzes by FIDELIO-DKD.
Below are links to two articles examining studies by Hui Shao, MD, PhD that focus on the rising costs of diabetes management.
PreviousNext
Finerenone data:
Insulin use background does not affect the benefits of finerenone in diabetic kidney disease
Finerenone offers constant benefits regardless of the background application of GLP-1 RA
Finerenone and SGLT2 inhibitors could have an additional effect on kidney protection
Diabetes costs:
Decreasing cost efficiency, a painful case for new blood sugar lowering agents
Estimating the Impact of the Medicare Part D Senior Savings Model on Insulin User Spending at Medicare
